Lumos与Double Point Ventures达成私有化协议

2024-10-23 20:24

Lumos Pharma (NASDAQ:LUMO) announced Wednesday a merger agreement with Double Point Ventures, under which the Florida-based venture capital firm is set to acquire the biotech in a take-private deal.
Per the terms, Double Point Ventures is set to buy Lumos Pharma's (NASDAQ:LUMO) common stock for $4.25 per share in cash plus a Contingent Value Right per share linked to certain milestones.
The rare-disease-focused biotech said its officers, directors, and shareholders owning about 17.7% of its stock have already agreed to tender their shares in support of the transaction. The deal is expected to close in Q2 2025.
Lumos (LUMO) also announced that the FDA has agreed to the company's proposed trial deals for its Phase 3 clinical study for its lead candidate LUM-201 in Pediatric Growth Hormone Deficiency. The global trial is expected to begin in Q2 2025, involving about 80 study sites.

More on Lumos Pharma